share_log

新銳醫藥：截至2024年2月29日之股份發行人的證券變動月報表

NEW RAY MEDIC: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024

香港交易所 ·  Mar 1 04:02
Summary by Moomoo AI
新銳醫藥國際控股有限公司於2024年2月29日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在2月份均無變動，維持在3,000,000,000股，每股面值0.05港元，總股本為150,000,000港元。此外，公司股份期權計劃下，截至2月底的股份期權結存數目為143,200,000，並無本月內變動。公司秘書吳日升確認，所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
新銳醫藥國際控股有限公司於2024年2月29日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在2月份均無變動，維持在3,000,000,000股，每股面值0.05港元，總股本為150,000,000港元。此外，公司股份期權計劃下，截至2月底的股份期權結存數目為143,200,000，並無本月內變動。公司秘書吳日升確認，所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
XINROI PHARMACEUTICAL INTERNATIONAL HOLDINGS LIMITED FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED ON 29 FEBRUARY 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged in February at 3,000,000,000 shares with a face value of HK$0.05 per share and a total share capital of HK$150,000,000. In addition, the number of stock options outstanding as of the end of February was 143,200,000 under the Company's stock option plan, which was unchanged during the month. Company Secretary Wu Zhisheng confirmed that all securities issuance has been authorised by the Board and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
XINROI PHARMACEUTICAL INTERNATIONAL HOLDINGS LIMITED FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED ON 29 FEBRUARY 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged in February at 3,000,000,000 shares with a face value of HK$0.05 per share and a total share capital of HK$150,000,000. In addition, the number of stock options outstanding as of the end of February was 143,200,000 under the Company's stock option plan, which was unchanged during the month. Company Secretary Wu Zhisheng confirmed that all securities issuance has been authorised by the Board and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more